Understanding Your Risk and Outlook

Understanding the prognosis for Myeloproliferative Neoplasm, Unclassifiable (MPN-U) can be challenging because the disease is so varied. Because there is no single “textbook” case of MPN-U, doctors use sophisticated tools to assess your individual risk level ^[1].

It is important to remember that statistics are based on large groups of people and cannot predict exactly what will happen in your specific case. However, they do help your care team decide how closely you need to be monitored and which treatments are most appropriate ^[2][3].

Survival and Risk Statistics

Research suggests that, as a group, patients with MPN-U often have a prognosis that falls between the more favorable outcomes of Polycythemia Vera (PV) and the more intensive outlook of Primary Myelofibrosis (PMF) ^[4].

• Event-Free Survival: One registry of 82 MPN-U patients found a median event-free survival of 11.25 years ^[5]. Event-free survival in this specific cohort measured the time until a major complication, but these historical registry estimates may not apply to your unique biology ^[5].
• 5-Year Survival: A large population study in Singapore found that about 74% of people with MPN-U were alive five years after their diagnosis ^[4]. These figures come from specific cohorts with varying definitions and treatments, and do not represent an expected course for an individual ^[4].

Assessing Your Risk: The DIPSS-Plus Score

Since MPN-U does not have its own dedicated scoring system, doctors often extrapolate using a model called DIPSS-plus (Dynamic International Prognostic Scoring System-plus) ^[1][3]. However, DIPSS-plus was developed and validated primarily for myelofibrosis, not for all MPN-U; risk assessment is highly individualized and may not map reliably to these categories. This tool helps categorize your disease into Low, Intermediate-1, Intermediate-2, or High risk based on several factors ^[6].

Factors in the DIPSS-Plus Score:

• Age: Being over 65 years old ^[6].
• Blood Counts: Hemoglobin below 10 g/dL, white blood cells over 25 x 10⁹/L, or platelets below 100 x 10⁹/L ^[6][7].
• Blasts: Having 1% or more “blast cells” (immature blood cells) in your bloodstream ^[6].
• Symptoms: Experiencing “constitutional symptoms” like night sweats, bone pain, or fever ^[6].
• Transfusions: Needing regular red blood cell transfusions ^[6].
• Karyotype: Certain abnormal findings in your chromosomes (the structures that hold your DNA) ^[6].

The Impact of Genetic Mutations

Beyond the “driver” mutations (JAK2, CALR, MPL), your doctor may look for “high-molecular-risk” mutations using Next-Generation Sequencing (NGS) ^[8].

• Specific Markers: Mutations in genes like ASXL1, SRSF2, and U2AF1 are often associated with a higher risk of the disease progressing to a more advanced stage ^[9][10].
• Blast Percentage: A higher percentage of blasts in your bone marrow is one of the strongest predictors of overall outlook in MPN-U ^[3].

A Critical Distinction: MPN-U vs. MDS/MPN

It is vital to ensure your diagnosis is a “classical” MPN-U (ICC) / MPN-NOS (WHO) and not a different entity called MDS/MPN-U (ICC) / MDS/MPN, NOS (WHO) ^[3][11]. While the names sound similar, they are biologically different.

If you are unsure which category you fall into, your pathology report is the best place to start. A “classical” MPN-U diagnosis means your cells look healthy and mature, but there are simply too many of them ^[1][5].